{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 36,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/35",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.88,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55be47b0-1fe6-48f9-8b24-40aafab69ab5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.66,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Boron Chemistry Platform: Novel biological targets in oncology and infectious disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18ed51e0-4e49-4f49-9458-a8e5e8b9bbac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Epetraborole in TR-MAC: Clinical endpoint POC in Phase 2; Near-term Phase 3 unblinding; Meeting with FDA on path forward",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae847ca9-ff52-4a60-bee9-972219ec3d27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Near-Term Catalysts Disciplined Capital Spend: Cash runway to 2027 allows for multiple potential inflection events",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbfc0e11-0b06-4c0f-88c0-1f20ec7e94d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Advancing Novel Therapies Using our Boron Chemistry Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88b0280b-fba7-4cf3-9bc3-5a0d06918a4e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}